Biomarkers have moved from “nice-to-have” to the backbone of drug development, says Quanterix’s Jorge Marques Signes, who argues they now shape feasibility, timelines and even payer expectations before sponsors commit thousands of patients or years of spend. “Biomarkers are not supplemental anymore,” said Marques Signes, VP of Accelerator & Clinical Services at Quanterix. “They are… The post Quanterix VP: Why biomarkers are no longer supplemental appeared first on Drug Discovery...| Drug Discovery and Development
Read our summary of a study by Dr. Akiko Iwasaki and her team that distinguishes groups of people with ME/CFS based on blood-plasma and cerebrospinal fluid proteins.| Solve ME/CFS Initiative
Do you experience weird head pressure sensations after floxing? Anecdotal information shows that these strange symptom are not so uncommon after all. The post Fluoroquinolone Associated Pseudotumor Cerebri appeared first on My Quin Story.| My Quin Story
